查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
亞太地區癲癇市場預測至 2030 年 - 區域分析 - 按類型、給藥途徑、治療類型、年齡層和配銷通路
市場調查報告書
商品編碼
1592587

亞太地區癲癇市場預測至 2030 年 - 區域分析 - 按類型、給藥途徑、治療類型、年齡層和配銷通路

Asia Pacific Epilepsy Market Forecast to 2030 - Regional Analysis - by Type, Route of Administration, Treatment Type, Age Group, and Distribution Channel
出版日期: | 出版商: The Insight Partners | 英文 146 Pages | 訂單完成後即時交付

價格

2022年亞太地區癲癇市場價值為22.0092億美元，預計到2030年將達到31.4344億美元；預計2022年至2030年複合年成長率為4.6%。

各組織所進行的意識激增計畫推動亞太地區癲癇市場發展

人們對癲癇及其症狀以及早期診斷重要性的認知不斷提高，導致尋求醫療救助的患者數量激增。癲癇基金會、癲癇協會、美國癲癇協會和佛羅裡達州中部癲癇協會等組織在教育人們了解這種疾病方面發揮著至關重要的作用。這些組織的參與提高了診斷率，並擴大了需要癲癇治療的患者群體。世界各地的組織開展了許多宣傳活動，以提高人們對這種疾病和可用治療的認知。 2023 年，在癲癇紫色日，印度海得拉巴的 Aster Prime 醫院與克里希納康德公園步行者協會合作舉辦了一場宣傳活動。共有一百五十名參與者，包括步行者和瑜伽練習者參加了本次活動。此外，為了改善澳洲癲癇患者的生活品質，澳洲癲癇行動組織提供各種工具和服務，旨在提高認知、教育個人並為他們提供必要的技能。因此，此類措施和宣傳活動導致癲癇診斷和治療的增加，為市場提供了利潤豐厚的成長機會。

亞太地區癲癇市場概況

我們根據中國、日本、印度、澳洲、韓國和亞太其他地區分析了亞太地區癲癇市場。根據世界衛生組織（WHO）報告，癲癇在發展中國家比已開發國家更為常見，盛行率分別為6.1%和5.0%。

亞太地區癲癇市場收入及 2030 年預測（百萬美元）

亞太地區癲癇市場細分

亞太地區癲癇市場按類型、給藥途徑、治療類型、年齡層、配銷通路和國家分類。

依類型，亞太地區癲癇市場分為進行性肌陣攣癲癇、反射性癲癇、全身性癲癇等。 2022 年，全身性癲癇細分市場佔最大市場。

就給藥途徑而言，亞太地區癲癇市場分為口服、腸胃外和其他。 2022 年，口腔細分市場佔據最大的市場佔有率。

依治療類型，亞太地區癲癇市場分為第一代藥物、第二代藥物和第三代藥物。 2022年，第三代藥物細分市場佔據最大市場佔有率。

根據年齡層，亞太地區癲癇市場分為成人和兒童。 2022 年，成人細分市場將佔據更大的市場佔有率。

從配銷通路來看，亞太癲癇市場分為醫院藥局、零售藥局等。 2022年，醫院藥局領域佔據最大的市場佔有率。

依國家分類，亞太地區癲癇市場分為中國、日本、印度、澳洲、韓國和亞太其他地區。 2022年，中國在亞太地區癲癇市場佔有率中佔據主導地位。

雅培實驗室、輝瑞公司、衛材有限公司、UCB SA、LivaNova Plc、諾華公司、美敦力公司、葛蘭素史克公司和 H. Lundbeck AS 是亞太地區癲癇市場的一些領導公司。

目錄

第 1 章：簡介

第 2 章：執行摘要

  • 主要見解
  • 市場吸引力

第 3 章：研究方法

  • 覆蓋範圍
  • 二次研究
  • 初步研究

第 4 章：亞太地區癲癇治療方法的管道研究

  • 癲癇治療方法的管道研究
    • 細胞和基因治療方法
    • 膠囊細胞生物遞送（ECB）系統
    • 癲癇基因治療臨床概述
      • 癲癇臨床研究採用基因療法
      • 癲癇病毒載體的管道研究
      • 癲癇非病毒載體的管道研究
      • 腺相關病毒 (AAV) 介導的神經調節胜肽 - 概述
      • 基因治療方法的神經營養因子
      • 人類癲癇表現型的鉀通道
      • 酶誘導抗癲癇藥

第 5 章：亞太地區癲癇市場 - 主要市場動態

  • 市場促進因素
    • 癲癇盛行率上升
    • 增加癲癇療法開發的投資
  • 市場限制
    • 產品召回
  • 市場機會
    • 組織所進行的意識計畫激增
  • 未來趨勢
    • 基因療法作為有前景的治療方法
  • 促進因素和限制的影響：

第 6 章：癲癇市場 - 亞太地區分析

  • 亞太地區：癲癇市場

第 7 章：亞太地區癲癇市場分析 - 按類型

  • 概述
  • 進行性肌陣攣癲癇
  • 反射性癲癇
  • 全身性癲癇
  • 其他

第 8 章：亞太地區癲癇市場分析 - 按給藥途徑

  • 概述
  • 口服
  • 注射用
  • 其他

第 9 章：亞太地區癲癇市場分析 - 按治療類型

  • 概述
  • 第一代藥物
  • 第二代藥物
  • 第三代藥物

第 10 章：亞太地區癲癇市場分析 - 按年齡層

  • 概述
  • 成人
  • 孩子們

第 11 章：亞太地區癲癇市場分析 - 按配銷通路

  • 概述
  • 醫院藥房
  • 零售藥局
  • 其他

第 12 章：亞太地區癲癇市場 - 國家分析

    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳洲
      • 韓國
      • 亞太地區其他地區

第 13 章：產業格局

  • 概述
  • 癲癇市場的成長策略
  • 有機成長策略
    • 概述
  • 無機成長策略
    • 概述

第 14 章：公司簡介

  • Abbott Laboratories
  • Pfizer Inc
  • Eisai Co Ltd
  • UCB SA
  • LivaNova Plc
  • Novartis AG
  • Medtronic Plc
  • GSK Plc
  • H. Lundbeck AS

第 15 章：附錄

Product Code: BMIRE00030724

The Asia Pacific epilepsy market was valued at US$ 2,200.92 million in 2022 and is expected to reach US$ 3,143.44 million by 2030; it is estimated to register a CAGR of 4.6% from 2022 to 2030.

Surge in Awareness Program Conducted by Organizations Boosts Asia Pacific Epilepsy Market

Growing awareness about epilepsy, its symptoms, and the importance of early diagnosis has led to a surge in patients seeking medical attention. Organizations such as the Epilepsy Foundation, Epilepsy Society, the American Epilepsy Society, and the Epilepsy Association of Central Florida play a crucial role in educating people about this disease. The involvement of these organizations has resulted in increased rates of diagnosis and a broader patient population requiring epilepsy treatment. Numerous awareness campaigns are conducted by organizations worldwide to spread awareness regarding the condition and available treatment. In 2023, on the Purple Day of Epilepsy, Aster Prime Hospitals in Hyderabad (India), in collaboration with the Walkers Association of Krishna Kant Park, held an awareness activity. One hundred fifty participants in total, including walkers and yoga practitioners, attended this session. Additionally, in order to improve the quality of life for Australians living with epilepsy, Epilepsy Action Australia offers a variety of tools and services aimed at raising awareness, educating, and equipping individuals with the necessary skills. Thus, such initiatives and awareness campaigns result in an increase in epilepsy diagnoses and treatments, offering lucrative growth opportunities to the market.

Asia Pacific Epilepsy Market Overview

The Asia Pacific epilepsy market is analyzed based on China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. According to the World Health Organization (WHO) report, epilepsy is more common in developing countries than in developed countries, accounting for a prevalence of 6.1% and 5.0%, respectively.

Asia Pacific Epilepsy Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Epilepsy Market Segmentation

The Asia Pacific epilepsy market is categorized into type, route of administration, treatment type, age group, distribution channel, and country.

Based on type, the Asia Pacific epilepsy market is categorized into progressive myoclonic epilepsy, reflex epilepsy, generalized epilepsy, and other. The generalized epilepsy segment held the largest market share in 2022.

In terms of route of administration, the Asia Pacific epilepsy market is categorized into oral, parenteral, and others. The oral segment held the largest market share in 2022.

By treatment type, the Asia Pacific epilepsy market is segmented into first generation drugs, second generation drugs, and third generation drugs. The third generation drugs segment held the largest market share in 2022.

Based on age group, the Asia Pacific epilepsy market is bifurcated into adult and children. The adult segment held a larger market share in 2022.

In terms of distribution channel, the Asia Pacific epilepsy market is categorized into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment held the largest market share in 2022.

By country, the Asia Pacific epilepsy market is segmented into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific epilepsy market share in 2022.

Abbott Laboratories, Pfizer Inc, Eisai Co Ltd, UCB SA, LivaNova Plc, Novartis AG, Medtronic Plc, GSK Plc, and H. Lundbeck AS are some of the leading companies operating in the Asia Pacific epilepsy market.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Asia Pacific Pipeline Studies for Epilepsy Therapy Approaches

  • 4.1 Pipeline Studies for Epilepsy Therapy Approaches
    • 4.1.1 Cell and Gene Therapy Approaches
    • 4.1.2 Encapsulated cell bio delivery (ECB) system
    • 4.1.3 Gene Therapy for Epilepsy Clinical Overview
      • 4.1.3.1 Genetic Therapies Adopted for Clinic Research of Epilepsy
        • 4.1.3.1.1 Gene Supplementation - Overview
        • 4.1.3.1.2 Gene Modulation - Overview
        • 4.1.3.1.3 Antisense Oligonucleotides and RNA Interference - Overview
        • 4.1.3.1.4 Neuropeptides - Overview
        • 4.1.3.1.5 Engineered Channels - Overview
        • 4.1.3.1.6 Endogenous Channels - Overview
      • 4.1.3.2 Pipeline Studies of Viral Vectors for Epilepsy
      • 4.1.3.3 Pipeline Studies of Non-Viral Vectors for Epilepsy
        • 4.1.3.3.1 Polymer-based Non-Viral Vectors for Epilepsy
        • 4.1.3.3.2 Lipid-based Non-Viral Vectors for Epilepsy
      • 4.1.3.4 Adeno-Associated Virus (AAV)-Mediated Neuromodulatory Peptides - Overview
      • 4.1.3.5 Neurotrophic Factors for Gene Therapy Approaches
      • 4.1.3.6 Potassium Channels For Human Epileptic Phenotypes
      • 4.1.3.7 Enzyme Inducing Antiepileptic Drugs

5. Asia Pacific Epilepsy Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Prevalence of Epilepsy
    • 5.1.2 Increasing Investments in Development of Epilepsy Therapies
  • 5.2 Market Restraints
    • 5.2.1 Recall of Products
  • 5.3 Market Opportunities
    • 5.3.1 Surge in Awareness Programs Conducted by Organizations
  • 5.4 Future Trends
    • 5.4.1 Gene Therapy as Promising Treatment Approach
  • 5.5 Impact of Drivers and Restraints:

6. Epilepsy Market - Asia Pacific Analysis

  • 6.1 Asia Pacific: Epilepsy Market

7. Asia Pacific Epilepsy Market Analysis - by Type

  • 7.1 Overview
  • 7.2 Progressive Myoclonic Epilepsy
    • 7.2.1 Overview
    • 7.2.2 Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.3 Reflex Epilepsy
    • 7.3.1 Overview
    • 7.3.2 Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Generalized Epilepsy
    • 7.4.1 Overview
    • 7.4.2 Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Other
    • 7.5.1 Overview
    • 7.5.2 Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Epilepsy Market Analysis - by Route of Administration

  • 8.1 Overview
  • 8.2 Oral
    • 8.2.1 Overview
    • 8.2.2 Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.3 Parenteral
    • 8.3.1 Overview
    • 8.3.2 Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Others
    • 8.4.1 Overview
    • 8.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Epilepsy Market Analysis - by Treatment Type

  • 9.1 Overview
  • 9.2 First Generation Drugs
    • 9.2.1 Overview
    • 9.2.2 First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.3 Second Generation Drugs
    • 9.3.1 Overview
    • 9.3.2 Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Third Generation Drugs
    • 9.4.1 Overview
    • 9.4.2 Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

10. Asia Pacific Epilepsy Market Analysis - by Age Group

  • 10.1 Overview
  • 10.2 Adult
    • 10.2.1 Overview
    • 10.2.2 Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 10.3 Children
    • 10.3.1 Overview
    • 10.3.2 Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

11. Asia Pacific Epilepsy Market Analysis - by Distribution Channel

  • 11.1 Overview
  • 11.2 Hospital Pharmacies
    • 11.2.1 Overview
    • 11.2.2 Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.3 Retail Pharmacies
    • 11.3.1 Overview
    • 11.3.2 Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • 11.4 Others
    • 11.4.1 Overview
    • 11.4.2 Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)

12. Asia Pacific Epilepsy Market - Country Analysis

  • 12.1 Asia Pacific Epilepsy Market Overview
    • 12.1.1 Asia Pacific: Epilepsy Market Breakdown, by Key Country, 2022 and 2030 (%)
      • 12.1.1.1 China: Epilepsy Market Overview
      • 12.1.1.2 China: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.2.1 China: Epilepsy Market Breakdown, by Type
        • 12.1.1.2.2 China: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.2.3 China: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.2.4 China: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.2.5 China: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.3 Japan: Epilepsy Market Overview
      • 12.1.1.4 Japan: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.4.1 Japan: Epilepsy Market Breakdown, by Type
        • 12.1.1.4.2 Japan: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.4.3 Japan: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.4.4 Japan: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.4.5 Japan: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.5 India: Epilepsy Market Overview
      • 12.1.1.6 India: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.6.1 India: Epilepsy Market Breakdown, by Type
        • 12.1.1.6.2 India: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.6.3 India: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.6.4 India: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.6.5 India: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.7 Australia: Epilepsy Market Overview
      • 12.1.1.8 Australia: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.8.1 Australia: Epilepsy Market Breakdown, by Type
        • 12.1.1.8.2 Australia: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.8.3 Australia: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.8.4 Australia: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.8.5 Australia: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.9 South Korea: Epilepsy Market Overview
      • 12.1.1.10 South Korea: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.10.1 South Korea: Epilepsy Market Breakdown, by Type
        • 12.1.1.10.2 South Korea: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.10.3 South Korea: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.10.4 South Korea: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.10.5 South Korea: Epilepsy Market Breakdown, by Distribution Channel
      • 12.1.1.11 Rest of Asia Pacific: Epilepsy Market Overview
      • 12.1.1.12 Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
        • 12.1.1.12.1 Rest of Asia Pacific: Epilepsy Market Breakdown, by Type
        • 12.1.1.12.2 Rest of Asia Pacific: Epilepsy Market Breakdown, by Route of Administration
        • 12.1.1.12.3 Rest of Asia Pacific: Epilepsy Market Breakdown, by Treatment Type
        • 12.1.1.12.4 Rest of Asia Pacific: Epilepsy Market Breakdown, by Age Group
        • 12.1.1.12.5 Rest of Asia Pacific: Epilepsy Market Breakdown, by Distribution Channel

13. Industry Landscape

  • 13.1 Overview
  • 13.2 Growth Strategies in Epilepsy Market
  • 13.3 Organic Growth Strategies
    • 13.3.1 Overview
  • 13.4 Inorganic Growth Strategies
    • 13.4.1 Overview

14. Company Profiles

  • 14.1 Abbott Laboratories
    • 14.1.1 Key Facts
    • 14.1.2 Business Description
    • 14.1.3 Products and Services
    • 14.1.4 Financial Overview
    • 14.1.5 SWOT Analysis
    • 14.1.6 Key Developments
  • 14.2 Pfizer Inc
    • 14.2.1 Key Facts
    • 14.2.2 Business Description
    • 14.2.3 Products and Services
    • 14.2.4 Financial Overview
    • 14.2.5 SWOT Analysis
    • 14.2.6 Key Developments
  • 14.3 Eisai Co Ltd
    • 14.3.1 Key Facts
    • 14.3.2 Business Description
    • 14.3.3 Products and Services
    • 14.3.4 Financial Overview
    • 14.3.5 SWOT Analysis
    • 14.3.6 Key Developments
  • 14.4 UCB SA
    • 14.4.1 Key Facts
    • 14.4.2 Business Description
    • 14.4.3 Products and Services
    • 14.4.4 Financial Overview
    • 14.4.5 SWOT Analysis
    • 14.4.6 Key Developments
  • 14.5 LivaNova Plc
    • 14.5.1 Key Facts
    • 14.5.2 Business Description
    • 14.5.3 Products and Services
    • 14.5.4 Financial Overview
    • 14.5.5 SWOT Analysis
    • 14.5.6 Key Developments
  • 14.6 Novartis AG
    • 14.6.1 Key Facts
    • 14.6.2 Business Description
    • 14.6.3 Products and Services
    • 14.6.4 Financial Overview
    • 14.6.5 SWOT Analysis
    • 14.6.6 Key Developments
  • 14.7 Medtronic Plc
    • 14.7.1 Key Facts
    • 14.7.2 Business Description
    • 14.7.3 Products and Services
    • 14.7.4 Financial Overview
    • 14.7.5 SWOT Analysis
    • 14.7.6 Key Developments
  • 14.8 GSK Plc
    • 14.8.1 Key Facts
    • 14.8.2 Business Description
    • 14.8.3 Products and Services
    • 14.8.4 Financial Overview
    • 14.8.5 SWOT Analysis
    • 14.8.6 Key Developments
  • 14.9 H. Lundbeck AS
    • 14.9.1 Key Facts
    • 14.9.2 Business Description
    • 14.9.3 Products and Services
    • 14.9.4 Financial Overview
    • 14.9.5 SWOT Analysis
    • 14.9.6 Key Developments

15. Appendix

  • 15.1 About The Insight Partners

List Of Tables

  • Table 1. Asia Pacific Epilepsy Market Segmentation
  • Table 2. Cell Therapy Approach - An Overview
  • Table 3. Gene Therapy Approach - An Overview
  • Table 4. Encapsulated cell bio delivery (ECB) system Cell and Gene Therapy Approach - An Overview
  • Table 5. Preclinically Tested Genetic Therapies for Epilepsy
  • Table 6. Clinical Trials for Epilepsy Gene Therapy: Overview
  • Table 7. Viral Vectors Comparison with respect to Various Parameters
  • Table 8. Subfamilies of Human K+ Channels Involved in Epilepsies
  • Table 9. Enzyme-Inducing Antiepileptic Drugs
  • Table 10. Enzyme-Inducing Antiepileptic Drugs & Drug Targets Types Overview
  • Table 11. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 12. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 13. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 14. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 15. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 16. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 17. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 18. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 19. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 20. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 21. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 22. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 23. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 24. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 25. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 26. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 27. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 28. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 29. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 32. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 33. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 34. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 35. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 36. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Type
  • Table 37. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Route of Administration
  • Table 38. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Treatment Type
  • Table 39. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Age Group
  • Table 40. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million) - by Distribution Channel
  • Table 41. Recent Organic Growth Strategies in Epilepsy Market
  • Table 42. Recent Inorganic Growth Strategies in the Epilepsy Market

List Of Figures

  • Figure 1. Asia Pacific Epilepsy Market Segmentation, by Country
  • Figure 2. Epilepsy Market - Key Market Dynamics
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Epilepsy Market Revenue (US$ Million), 2020-2030
  • Figure 5. Epilepsy Market Share (%) - by Type (2022 and 2030)
  • Figure 6. Progressive Myoclonic Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 7. Reflex Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Generalized Epilepsy: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Other: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Epilepsy Market Share (%) - by Route of Administration (2022 and 2030)
  • Figure 11. Oral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. Parenteral: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 13. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Epilepsy Market Share (%) - by Treatment Type (2022 and 2030)
  • Figure 15. First Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Second Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. Third Generation Drugs: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 18. Epilepsy Market Share (%) - by Age Group (2022 and 2030)
  • Figure 19. Adult: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. Children: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 21. Epilepsy Market Share (%) - by Distribution Channel (2022 and 2030)
  • Figure 22. Hospital Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Retail Pharmacies: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Others: Epilepsy Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 25. Asia Pacific: Epilepsy Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 26. Asia Pacific: Epilepsy Market Breakdown, by Key Countries, 2022 and 2030 (%)
  • Figure 27. China: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 28. Japan: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 29. India: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 30. Australia: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 31. South Korea: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 32. Rest of Asia Pacific: Epilepsy Market - Revenue and Forecast to 2030(US$ Million)
  • Figure 33. Growth Strategies in Epilepsy Market